GPCR profiling: from hits to leads and from genotype to phenotype

Eglen, 2006, Deja vu all over again: emerging concepts of G protein-coupled receptor (GPCR) function and drug discovery, Drug Discov World, 6, 69 Rask-Andersen, 2011, Trends in the exploitation of novel drug targets, Nat Rev Drug Discov, 10, 579, 10.1038/nrd3478 2014, G-Protein Coupled Receptor (GPCR) targeting: technologies and global markets, BCC Res Bowes, 2012, Reducing safety-related drug attrition: the use of in vitro pharmacological profiling, Nat Rev Drug Discov, 11, 909, 10.1038/nrd3845 Roth, 2007, Drugs and valvular heart disease, N Engl J Med, 356, 6, 10.1056/NEJMp068265 Olasinska-Wisniewska, 2014, Cardiovascular safety of antihistamines, Postepy Dermatol Alergol, 31, 182, 10.5114/pdia.2014.43191 Rodgers, 2012, Anti-obesity drugs: past, present and future, Dis Model Mech, 5, 621, 10.1242/dmm.009621 Eglen, 2011, GPCRs revisited: new insights lead to novel drugs, Pharmaceuticals, 4, 244, 10.3390/ph4020244 Conn, 2014, Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders, Nat Rev Drug Discov, 13, 692, 10.1038/nrd4308 Zhang, 2012, Case study: technology initiative led to advanced lead optimization screening processes at Bristol-Myers Squibb, 2004-2009, Drug Discov Today, 17, 733, 10.1016/j.drudis.2012.02.012 Jacoby, 2006, The 7 TM G-protein-coupled receptor target family, ChemMedChem, 1, 761, 10.1002/cmdc.200600134 Rodriguez, 2010, Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity, Mol Pharmacol, 78, 1105, 10.1124/mol.110.067207 Smith, 2015, Application of parallel multiparametric cell-based flipr detection assays for the identification of modulators of the muscarinic acetylcholine receptor 4 (M4), J Biomol Screen, 20, 858, 10.1177/1087057115581770 Kostenis, 2005, Techniques: promiscuous Gα proteins in basic research and drug discovery, Trends Pharmacol Sci, 26, 595, 10.1016/j.tips.2005.09.007 Noblin, 2012, Development of a high-throughput calcium flux assay for identification of all ligand types including positive, negative, and silent allosteric modulators for G protein-coupled receptors, Assay Drug Dev Technol, 10, 457, 10.1089/adt.2011.443 Bertekap, 2015, High-throughput screening for allosteric modulators of GPCRs, 223 Zhang, 2012, Tools for GPCR drug discovery, Acta Pharmacol Sin, 33, 372, 10.1038/aps.2011.173 Zhang, 2009, Screening and characterization of G-protein-coupled receptor ligand for drug discovery Cvijic, 2012, GPCR assay automation for leveraging lead optimization, J Lab Autom, 17, 266, 10.1177/2211068212442502 Allen, 2011, Strategies to discover unexpected targets for drugs active at G protein-coupled receptors, Annu Rev Pharmacol Toxicol, 51, 117, 10.1146/annurev-pharmtox-010510-100553 Cusack, 2015, Design strategies to address kinetics of drug binding and residence time, Bioorg Med Chem Lett, 25, 2019, 10.1016/j.bmcl.2015.02.027 Lewis, 2015, Discovery of D1 dopamine receptor positive allosteric modulators: characterization of pharmacology and identification of residues that regulate species selectivity, J Pharmacol Exp Ther, 354, 340, 10.1124/jpet.115.224071 Azzi, 2003, Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors, Proc Natl Acad Sci U S A, 100, 11406, 10.1073/pnas.1936664100 DeWire, 2011, Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology, Circ Res, 109, 205, 10.1161/CIRCRESAHA.110.231308 Violin, 2014, Biased ligands at G-protein-coupled receptors: promise and progress, Trends Pharmacol Sci, 35, 308, 10.1016/j.tips.2014.04.007 Griffin, 2007, Estimation of agonist activity at G protein-coupled receptors: analysis of M2 muscarinic receptor signaling through Gi/o,Gs, and G15, J Pharmacol Exp Ther, 321, 1193, 10.1124/jpet.107.120857 Kenakin, 2012, A simple method for quantifying functional selectivity and agonist bias, ACS Chem Neurosci, 3, 193, 10.1021/cn200111m Gregory, 2010, Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias, J Biol Chem, 285, 7459, 10.1074/jbc.M109.094011 van der Westhuizen, 2014, Quantification of ligand bias for clinically relevant beta2-adrenergic receptor ligands: implications for drug taxonomy, Mol Pharmacol, 85, 492, 10.1124/mol.113.088880 Zhu, 2014, Integrating high-content analysis into a multiplexed screening approach to identify and characterize GPCR agonists, J Biomol Screen, 19, 1079, 10.1177/1087057114533146 Scott, 2010, Label-free whole-cell assays: expanding the scope of GPCR screening, Drug Discov Today, 15, 704, 10.1016/j.drudis.2010.06.008 Fang, 2014, Label-free drug discovery, Front Pharmacol, 5, 52, 10.3389/fphar.2014.00052 Navratilova, 2011, Screening for GPCR ligands using surface plasmon resonance, ACS Med Chem Lett, 2, 549, 10.1021/ml2000017 Burford, 2011, Strategies for the identification of allosteric modulators of G-protein-coupled receptors, Biochem Pharmacol, 81, 691, 10.1016/j.bcp.2010.12.012 Sharma, 2008, Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold, Bioorg Med Chem Lett, 18, 4098, 10.1016/j.bmcl.2008.05.091